#cannabisaficionado

Cannabis

Cannabis DNA Tests Can Tell You How Your Body Responds to Weed

Cannabis DNA tests provide an access point for preventative precision cannabis medicine, customized as a function of the consumer’s genetic predispositions.

Published

on

Cannabis DNA Tests
PHOTO | Adobe Stock
Advertisement Back2Grow Advertisement

There is a high probability that the following scene has played out at least once in your life: after passing a joint around a smoke circle, one person can’t stop laughing at the painting they insist is moving, another is proclaiming the profundities of Kenrick Lamar’s lyricism, and yet another is “resting their eyes”. While humorous to observe the panoply of personalities, this setting provides an important observation. The cannabinoids and terpenes found in different cannabis products interact with everyone’s internal biochemistry differently.

Naturally, aspects of your lifestyle like how much exercise you’ve been getting, your sleep patterns, and diet all play a role in how you’ll respond to a cannabis product on any given day. However, the most critical factor is the makeup of your endocannabinoid system — the chemicals and neurons in your brain and body that respond to cannabinoids. Your DNA holds the specific instructions for how your endocannabinoid system gets “wired up” compared to other people, permitting for individual differences in reactions to cannabis.

A Quick Introduction to DNA

DNA (deoxyribonucleic acid) is a long molecule that contains the instructions for building every single part of an organism. DNA is made up of four compounds that pair up: (A) Adenine, (T) Thymine, (C) Cytosine, and (G) Guanine. 99.5% of the base pair combinations that make up humans are identical from person to person. The .5% difference is what makes you unique. Variants are the genetic differences that make up that .5%.

You may be familiar with the term “gene”, which is simply a section of DNA that carries the codes for making and organizing specific molecules that eventually serve as the building blocks for different parts and functions of an organism. Variants at specific genes have been identified as the determinants for thousands of different traits, from whether you’ll have blue or green eyes to whether or not you’ll have muscular dystrophy. As new research is conducted on cannabis and the body, more genetic links that can predict your response to cannabis are beginning to surface.

How Your DNA Affects Your Cannabis Consumption

PHOTO | Strain Genie

With genes holding the instructions for the creation of enzymes and proteins that go on to make up all the constituents of your brain and body, it is a small leap of understanding to see how variants at specific genes can affect your endocannabinoid system and, subsequently, your experience with cannabis.

An extreme example of this is Clinical Endocannabinoid Deficiency (CECD) — a genetic condition where the carrier’s body produces significantly less endogenous cannabinoids and receptors as compared to a healthy person. CECD presents an obvious linkage between DNA and cannabis use: if you carry a gene for CECD, you will require substantially more cannabis in order to achieve the same effects as someone without that gene. Other genetic links that predict your response to cannabis can be a bit more insidious.

Take the genes CYP2C9 and CYP2C19 for example; they code for an enzyme that breaks down THC and CDD respectively. Variants on these genes can make the enzymes they create up to 30% less effective. This means that consumers with those variants would be less effective in breaking down THC and CBD.

This breakdown process is a critical variable to consider when ingesting chemicals. In fact, some pharmaceuticals specifically take this breakdown system into account by creating drugs that inhibit the breakdown of endogenous chemicals so that they can remain effective longer and produce “more” of their intended outcome. For example, SSRIs (Selective Serotonin Reuptake Inhibitors; the leading anti-depressant) delay the breakdown of serotonin (a positive mood-regulating neurotransmitter) in the synapse (the small space that allows transmission of neurotransmitters across neurons) so that an individual’s serotonin (which is usually not as present in depressed populations) can continue to operate, yielding a “happier” person. Similarly, the sluggish breakdown of THC will result in a user feeling “higher” for longer. Unfortunately, this also creates drowsiness in users with the variant for up to three days after initial consumption.

Naturally, insights into which variants on the CYPC9 and CYP2C19 an individual has can help guide dosage and titration models as well identify which product categories to choose. For example, a consumer that is pre-disposed to sub-optimal breakdown would be wise to choose vape products over edible since inhalation bypasses what is known as first-pass metabolism, which occurs in the liver after during digestion of edible. Such information into drug metabolism has fueled the burgeoning field of pharmacogenetics, where medical doctors take a personalized approach to pharmaceutical medication based on the patient’s DNA.

DNA Insights for Personalized Cannabis Use

PHOTO | Strain Genie

The effectiveness of cannabis as a treatment option for a wide variety of disorders and diseases, coupled with the reliability of DNA in determining an individual’s likelihood of developing a particular condition, provides an access point for preventative precision cannabis medicine, customized as a function of the consumer’s genetic predispositions.

Taking into account the tens of thousands of cannabis products and strains available on the legal market, there exist a plethora of options with varying cannabinoid and terpene ratios — the most critical variables that determine the different effects and medical benefits of cannabis.

Such a range of products, coupled with an understanding of one’s DNA, allows for a personalized product selection by connecting the dots across different research findings. These biomarkers can create even more precise recommendations that go much further than just warning an individual that they should shy away from edibles.

For example, a host of genes can predispose someone to developing Alzheimer’s and dementia. On the other side of the equation, studies have shown that pinene (a terpene found in cannabis and other plants like pine trees) has a neuroprotective effect that specifically enhances memory. Cannabis users with such predispositions wanting to take preventative health measures could do so by routinely choosing cannabis products high in pinene.

Similar associations exist for users with a tendency to develop schizophrenia or have psychotic episodes, where low-THC, high-CBD products can provide anti-psychotic effects. Similar reasoning applies to individuals at a high-risk for cancer being able to take advantage of high-THC, anti-cancer products.

Cannabis DNA tests like Strain Genie look at over 150 such biomarkers to generate personalized cannabis consumption suggestions.

As regulation allows for scientists to gain access to cannabis for research studies, more insights that can help predetermine the effectiveness of cannabis use at the level of an individual is certainly on the horizon. Other avenues could also provide insights as to other aspects of cannabis use as well. For example, new research from 2018 has even unveiled 35 genes that make you 11% more likely to be a cannabis consumer and revealed an interesting overlap in cannabis use with a gene (CADM2) that has been traditionally associated with risk-taking. Information such as this, combined with genes that predispose individuals for abuse could be used to guide scheduled tolerance breaks.

Regardless of the application, additional research into DNA, cannabinoids, and terpenes promises to refine the personalized approach to cannabis that all consumers should consider taking.

Cannabis

Alaska Weighs Two Cannabis Purchase-Limit Models Ahead of November 18–19 Meeting

Two draft approaches would raise Alaska’s concentrate allowance, but their THC calculations and the next rulemaking steps need to be read separately.

Published

on

Close-up of an empty black digital kitchen scale on a brown surface

Alaska’s Marijuana Control Board is due to consider two draft approaches to cannabis purchase limits at its November 18–19 meeting. Both would raise the concentrate allowance, but the drafts do not describe the same THC limit. For consumers and retailers, the distinction is more useful than a blanket claim that Alaska is doubling everything.

These are documents for board consideration, not new limits already available at a shop. Anthony Martinelli’s reporting for The Marijuana Herald highlighted the proposals this week. The state’s packet allows readers to compare the actual alternatives and the decisions still ahead.

Start with the rule that applies today

The state’s published marijuana regulations set daily retail ceilings of one ounce of usable marijuana, seven grams of concentrate for inhalation and 5,600 milligrams of THC in combined marijuana and marijuana-product sales. The sales-limit section includes purchases for on-site consumption within its coverage.

Separate on-site rules are narrower: an endorsed retailer may sell up to one gram of flower, edible products containing up to 25 milligrams of THC, or a vaping device containing no more than 0.3 grams of concentrate to one person per day. Those existing figures are the baseline for assessing the proposed changes.

Weight, cannabinoid content and the setting of a sale are different measurements. A gram of concentrate is not a milligram of THC, and an allowance at a retail counter does not necessarily describe the amount that may be sold for immediate consumption in a licensed area.

The two alternatives need separate calculations

The November 9 staff memorandum and attached drafts include one model using 28 grams of usable marijuana, 14 grams of inhalable concentrate and 11,200 milligrams of combined THC, with maximum quantities assigned 100 point-of-sale units. The other uses a one-ounce flower equivalent: 14 grams of concentrate or 140 ten-milligram servings in products.

That second product equivalent totals 1,400 milligrams. It is not the first model’s 11,200-milligram figure. Both drafts would align endorsed on-site sales with the retail limits and remove the present concentrate-vaping-only restriction. The packet presents alternatives, not a combined package in which every favorable figure can be selected at once.

For a retailer, the eventual calculation would need to be translated into a checkout system and clear staff instructions. For a customer buying several product types, the important question would be how the final rule treats the combination. Neither can be answered by reading only the proposed concentrate weight.

A wider regulatory review is driving the work

The project is part of Governor Mike Dunleavy’s Administrative Order 360, issued August 4, 2025. It directs executive agencies to review requirements that are outdated, redundant or unclear, with reduction targets of 15 percent by the end of 2026 and 25 percent cumulatively by the end of 2027.

The order also calls for early stakeholder engagement, legally sound rules and continued critical consumer protection. It is a broad instruction to review the regulatory system. It does not itself replace the numerical cannabis sales limits or decide which of the two drafts should advance.

The order asks agencies to document public feedback and their responses. That creates a useful test for following this project: the public record should explain the problem being addressed and why a particular calculation was chosen. A reduced requirement count alone cannot tell shoppers how to compare products, or tell retailers whether their checkout software will apply the intended ceiling correctly.

That context makes the quality of the eventual language significant. Simplification can mean making a calculation easier to understand, as well as changing its ceiling. A useful final rule would let a customer, cashier and inspector reach the same answer about a mixed purchase without relying on conflicting summaries.

What the board can do next

The memorandum lists several possible actions: advance a draft for Department of Law review and subsequent public comment, amend it first, return it to staff, table it or close the project. A decision to move forward would therefore be another step in rulemaking, rather than proof that new limits take effect immediately.

The official meeting notice places the session in Anchorage beginning at 9 a.m. Alaska time. It specifies the Robert B. Atwood Building, with different arrangements for the two days, and provides remote-access information. Readers planning to attend should check those official details rather than assume both days use the same room.

Our coverage of proposed Portland retail changes follows a similar distinction between a proposal and permission to operate under it. In Alaska, the next meaningful update is the board’s recorded action, the precise draft it advances and any later public-comment notice. Until then, the current rules remain the practical reference.

Illustrative stock photograph of a kitchen scale; not cannabis testing equipment or an Alaska retail transaction. Photo: Bimbim Sindu / Pexels.

Continue Reading

Health

Utah’s Proposed Cannabis Voucher Rules Put Patient Costs and Pharmacy Access in Focus

Utah is building the operating rules for medical cannabis assistance, with eligibility, available funding and the nonprofit administrator still central to access.

Published

on

A person holding U.S. dollar bills above an open black wallet

Utah has proposed operating rules for its medical cannabis patient-voucher program, adding detail about how financial assistance would reach patients and pharmacies. The November 15 filing addresses $150 patient accounts, delivery costs and access across licensed pharmacies. It is a step toward implementation, rather than an announcement that every eligible patient can collect a voucher today.

The proposal appears as R67-7 in the Utah State Bulletin. Comments are accepted through December 15. The filing identifies December 22 as a possible effective date and expressly distinguishes that anticipated date from an actual effective date. Patients should therefore look for the completed rulemaking and program instructions before relying on a start date.

Eligibility comes from the law, not a shop promotion

Senate Bill 121’s enrolled text created the program in Section 26B-4-248. It authorizes a contracted nonprofit to provide monthly $150 vouchers, subject to available funds. Eligibility requires an active medical cannabis patient card and enrollment in Medicaid or Medicare. The bill took effect May 6, 2026.

That is a defined group, rather than all adults with a low income or everyone who buys cannabis for health reasons. A patient needs to distinguish qualification for the medical cannabis program from qualification for this particular financial assistance. Meeting one set of requirements does not automatically establish the other.

The law also requires quarterly accounting and directs the contracted nonprofit to use the money it receives under the provision for vouchers. The assistance is tied to purchases through medical cannabis pharmacies, rather than an unrestricted cash payment that can be used for unrelated household spending.

The grant process is for the administrator

The state’s patient-voucher grant page says applications to administer the program close December 15. A review team will choose one nonprofit. This application is for an organization to operate the assistance system; it should not be confused with an application by a patient seeking an individual voucher.

The page identifies funding of up to $300,000 per fiscal year from the Qualified Patient Enterprise Fund, with the exact amount dependent on available funds. It asks applicants to explain patient verification, voucher issuance, reimbursement and timelines. The nonprofit would reimburse pharmacies after patients use the assistance.

That funding qualification matters. A stated monthly amount describes the intended benefit, while an annual pool describes the resources supporting the program. Neither number, by itself, tells a patient when an application will be processed or guarantees that every potentially eligible person will receive assistance for every month.

The grant requirements include accessible applications, annual checks of Medicaid or Medicare eligibility, protection of patient information and oversight intended to prevent pharmacies from overcharging voucher users. Those administrative details affect whether assistance is usable in practice, especially for someone who needs help navigating an application or cannot easily travel.

What the proposed rule would add

The draft caps each patient account at $150 and would permit redemption for medical cannabis products, state transaction fees and delivery fees at any licensed Utah medical cannabis pharmacy, including during sales or promotions. It also calls for written reasons and appeal information when a voucher is denied.

For patients, those provisions connect the headline benefit to the actual checkout cost. Delivery and transaction charges can consume part of a budget before the product itself is considered. Pharmacy-wide redemption would make the benefit different from a discount usable only at one participating business, although implementation still depends on the final rules and operating system.

The Marijuana Herald’s November 16 report drew attention to the filing and its delivery-fee provisions. The original documents clarify two separate dates on December 15: the proposed rule’s comment deadline and the grant application deadline for an administrator.

Assistance and clinical access remain separate

The state’s 2026 medical cannabis law summary places vouchers alongside other program changes, including the transfer of remaining health-department duties to the Department of Agriculture and Food by January 1, 2027. It says providers, patients and industry will be informed when the transition is complete.

The summary also distinguishes low-THC medical products sold through pharmacies from separately regulated hemp products. Financial assistance should be read within that medical-program framework, rather than as a general subsidy for any product advertised with a cannabis or CBD label.

Our coverage of Iowa’s patient sales-tax recommendation examines a different approach to patient cost. Utah’s immediate questions are operational: who will administer the grant, what the final rule requires and when patients will receive clear application instructions. Those answers will determine how the promised assistance reaches the people it is intended to help.

Illustrative stock budgeting photograph; not a Utah patient, voucher or program payment. Photo: Towfiqu barbhuiya / Pexels.

Continue Reading

Cannabis

North Carolina’s Cannabis Council Returns to Draft Market Rules on November 17

The November 17 agenda puts draft recommendations before North Carolina’s cannabis council, with competing retail models and a December report still ahead.

Published

on

A black microphone on a stand in front of empty conference chairs

North Carolina’s Advisory Council on Cannabis is scheduled to discuss draft recommendations November 17, with the design of a possible regulated cannabis market still unsettled. The meeting gives residents and businesses another chance to follow how the council weighs retail access, oversight and public safety. It does not open a legal statewide recreational market or award anyone a license.

The official agenda lists a 1:30–5 p.m. meeting at the Department of Health and Human Services headquarters in Raleigh. Most of the scheduled session is reserved for member discussion of draft recommendations, following updates on public comments and approval of earlier minutes.

A discussion stage, with a report still ahead

The timing deserves care. October subcommittee minutes describe November 17 as a meeting to finalize recommendations, while identifying December 1 for an internal report draft and December 15 for a council vote on the final report. That sequence does not establish that Tuesday’s meeting will produce an adopted final document. The published agenda itself promises discussion, rather than a completed legislative package.

Anthony Martinelli’s reporting for The Marijuana Herald drew attention to the meeting and the competing market structures in the minutes. The underlying documents are particularly useful because they show which proposals remain options, instead of presenting one model as North Carolina’s settled plan.

Three retail approaches remain in view

The October 23 Market and Regulatory Subcommittee minutes describe state-controlled retail, a private market and a hybrid involving state warehousing with roughly 400 privately owned dispensaries. Members agreed to present leading models with their advantages and disadvantages rather than force a single consensus.

The approximate store count belongs to that floated hybrid, not an approved statewide license allocation. Treating it as a commitment would skip the decisions about market structure, legislation and implementation. The minutes also identify legal concerns about state employees handling a substance that remains subject to federal restrictions.

That disagreement affects more than the name above a shop door. Retail ownership, wholesale distribution and cultivation licensing determine different parts of the supply chain. A system can permit private farming while placing distribution or retail under another structure. Readers assessing the eventual recommendations should track those functions separately.

Licensing and oversight are separate choices

The subcommittee recorded broad agreement on separate cultivation, processing and retail licenses rather than mandatory vertical integration. It also considered an independent regulatory commission or oversight within an existing agency. Those are distinct design decisions: who may run a business and who supervises the market.

Either approach would require workable staffing and enforcement. For a prospective operator, a license category alone cannot answer what an application will cost, how inspections will work or whether related companies can hold multiple licenses. The eventual report and any legislation would need to make those details clearer.

There is a parallel question about existing hemp sellers. A transition into a new framework would require decisions about which products and businesses fall within it, and what happens during the change. The minutes identify that transition as an open issue. They do not establish a guaranteed route into a future cannabis market for every current retailer.

The October discussion also considered a separate channel for low-dose THC beverages, potentially through licensed outlets beyond dispensaries. The minutes describe safeguards such as age checks and testing. These remain ideas under consideration, not new permission for a grocery store or bar to sell a particular product. Whether beverages follow the same distribution route as other cannabis products is one of the questions members still need to resolve.

The council’s job is to recommend

Governor Josh Stein’s executive order establishing the council directs it to study and recommend a comprehensive approach grounded in public health and safety. Its remit brings together perspectives from government, agriculture, law enforcement and other groups. Creating an advisory body is different from enacting the laws necessary for a statewide sales system.

The council’s public page includes the meeting agenda, a viewing link and a public-comment route. Those are the appropriate starting points for following the process. Participation should be based on the current official instructions, especially if meeting arrangements change.

For consumers, the practical question is what protections a proposal would attach to access. For businesses, it is how licensing, distribution and oversight fit together. Our coverage of Missouri’s market boundaries illustrates why a change in one part of cannabis policy should not be mistaken for permission to operate everywhere.

Tuesday’s useful outcome will be a clearer account of the recommendations members support and the disagreements they retain. The record after the meeting, followed by the draft report and later vote, will show how much of the proposed framework has actually advanced.

Illustrative stock conference photograph; not the North Carolina council meeting or its venue. Photo: Borta / Pexels.

Continue Reading

Trending

Join The Cannabis Aficionado Community!
Join the Cannabis Aficionado community and receive all of the most relevant news geared towards our sophisticated enthusiast community.
Loading

Copyright ©️ 2026 Cannabis Aficionado. Cannabis Aficionado is a registered trademark of CNM Inc. All rights reserved. Registration on or use of this site constitutes acceptance of our Terms of Service, Privacy Policy and Cookies Policy. People may receive compensation for some links to products and services. Offers may be subject to change without notice.